Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sanhanhuashi granules versus Paxlovid for mild to moderate COVID-19
ChiCTR2300067872Phase 4Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sanhanhuashi and Nirmatrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: Time from COVID-19-related symptoms to sustained clinical recovery. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
sanhanhuashiNirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300067872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067872.